Iodine I 131 Iopofosine · I-131, CLR-131

What is Iodine I 131 Iopofosine?

Iodine I 131 iopofosine is a radioconjugate of iopofosine, a phospholipid ether analog labeled with the radioactive isotope iodine-131. It selectively accumulates and is retained in tumor cells, which have decreased phospholipase D activity compared with normal cells, delivering cytotoxic radiation to them. It is studied in B-cell lymphomas, chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, multiple myeloma and glioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

I-131, CLR-131, Iopofosine I 131, 131I-CLR1404

Drug type

Radiopharmaceutical

Mechanism

Cytotoxic

Pathways

phospholipid metabolism, radiation-induced cytotoxicity

Therapy area

Oncology

Developer

Cellectar Biosciences, Inc. (CLRB)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

R048696O9L

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Central Nervous System LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaHigh-Grade GliomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaWaldenstrom MacroglobulinaemiaWaldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia With Nodal DiseaseWaldenstrom's Macroglobulinaemia RefractoryWaldenstrom's Macroglobulinemia RecurrentGlioma

More from Cellectar Biosciences

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT02278315
• ClinicalTrials.gov NCT02278315
• ClinicalTrials.gov NCT05610891

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLRB page.